DE4031881C2
(de)
*
|
1990-10-08 |
1994-02-24 |
Sanol Arznei Schwarz Gmbh |
Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
|
DK0580860T4
(da)
†
|
1991-04-16 |
2005-03-21 |
Nippon Shinyaku Co Ltd |
Fremgangsmåde til fremstilling af en fast dispersion
|
JP2640570B2
(ja)
*
|
1992-01-13 |
1997-08-13 |
ファイザー インク. |
強度が増加した錠剤の製造
|
JPH0656659A
(ja)
*
|
1992-06-10 |
1994-03-01 |
Natl Sci Council |
直接打錠できる薬学組成物及びその錠剤の製造法
|
US5700410A
(en)
*
|
1992-10-16 |
1997-12-23 |
Nippon Shinyaku Co., Ltd. |
Method of manufacturing wax matrices
|
IL110139A0
(en)
*
|
1993-06-28 |
1994-10-07 |
Howard Foundation |
Pharmaceutically-active antioxidants
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
DE19629753A1
(de)
|
1996-07-23 |
1998-01-29 |
Basf Ag |
Verfahren zur Herstellung von festen Arzneiformen
|
TW474824B
(en)
|
1996-09-13 |
2002-02-01 |
Basf Ag |
The production of solid pharmaceutical forms
|
DE19710213A1
(de)
*
|
1997-03-12 |
1998-09-17 |
Basf Ag |
Verfahren zur Herstellung von festen Kombinationsarzneiformen
|
DE19753298A1
(de)
|
1997-12-01 |
1999-06-02 |
Basf Ag |
Verfahren zur Herstellung von festen Dosierungsformen
|
CA2314893C
(fr)
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
Combinaison d'agonistes et d'antagonistes d'opioides
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
DE19812688A1
(de)
|
1998-03-23 |
1999-09-30 |
Basf Ag |
Verfahren zur Herstellung von festen Dosierungsformen
|
DE19840256A1
(de)
|
1998-09-03 |
2000-03-09 |
Basf Ag |
Verfahren zur Herstellung von beschichteten festen Dosierungsformen
|
DE19841244A1
(de)
|
1998-09-09 |
2000-03-16 |
Knoll Ag |
Verfahren und Vorrichtung zum Herstellen von Tabletten
|
DE19843904A1
(de)
|
1998-09-24 |
2000-03-30 |
Basf Ag |
Feste Dosierungsform mit polymerem Bindemittel
|
DE19847618A1
(de)
|
1998-10-15 |
2000-04-20 |
Basf Ag |
Verfahren zur Herstellung von festen Dosierungsformen
|
DE19901383A1
(de)
|
1999-01-15 |
2000-07-20 |
Knoll Ag |
Verfahren zur Herstellung unterschiedlicher fester Dosierungsformen
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
MXPA02004293A
(es)
|
1999-10-29 |
2002-10-31 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada..
|
EP1175205B1
(fr)
*
|
1999-11-12 |
2006-06-14 |
Abbott Laboratories |
Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
DE19960494A1
(de)
*
|
1999-12-15 |
2001-06-21 |
Knoll Ag |
Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
|
DE60135441D1
(de)
|
2000-02-08 |
2008-10-02 |
Euro Celtique Sa |
Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
|
EP1299104B1
(fr)
|
2000-02-08 |
2009-05-13 |
Euro-Celtique S.A. |
Formes orales inviolables a base d'agonistes opioides
|
DE10017102A1
(de)
|
2000-04-06 |
2001-10-11 |
Basf Ag |
Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
EP1337244A4
(fr)
|
2000-10-30 |
2006-01-11 |
Euro Celtique Sa |
Preparations d'hydrocodone a liberation lente
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
CA2457361C
(fr)
|
2001-08-06 |
2008-11-04 |
Christopher Breder |
Formulations d'agoniste opioide a antagoniste liberable et sequestre
|
WO2003013433A2
(fr)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Formulations d'antagoniste sequestre
|
EP2425821B1
(fr)
|
2002-04-05 |
2017-05-10 |
Euro-Celtique S.A. |
Préparation pharmaceutique contenant de l'oxycodone et de la naloxone
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
EP2422773A3
(fr)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Séquestration de sous-unité et compositions et procédés associés
|
DE10247037A1
(de)
*
|
2002-10-09 |
2004-04-22 |
Abbott Gmbh & Co. Kg |
Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
|
EP2218448B1
(fr)
|
2002-12-13 |
2015-09-23 |
Durect Corporation |
Forme d'administration orale de medicaments comprenant un vehicule liquide de haute viscosite
|
JP2006511541A
(ja)
*
|
2002-12-17 |
2006-04-06 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
フェノフィブル酸、その生理学的に許容し得る塩または誘導体を含有してなる製剤
|
US20080051411A1
(en)
*
|
2002-12-17 |
2008-02-28 |
Cink Russell D |
Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
|
WO2004069180A2
(fr)
*
|
2003-01-31 |
2004-08-19 |
Smithkline Beecham Corporation |
Compositions solides de dispersion
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
JP5501553B2
(ja)
|
2003-04-21 |
2014-05-21 |
ユーロ−セルティーク エス.エイ. |
同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
|
US8075872B2
(en)
*
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
PL1663229T3
(pl)
|
2003-09-25 |
2010-09-30 |
Euro Celtique Sa |
Farmaceutyczne kombinacje hydrokodonu i naltreksonu
|
BRPI0417348A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
|
WO2005053652A1
(fr)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
|
BRPI0417360A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
método para a preparação de multiparticulados farmacêuticos
|
JP2007513146A
(ja)
*
|
2003-12-04 |
2007-05-24 |
ファイザー・プロダクツ・インク |
液体系プロセスによるアジスロマイシンマルチパーティキュレート剤形
|
EP1691786A1
(fr)
*
|
2003-12-04 |
2006-08-23 |
Pfizer Products Inc. |
Compositions multiparticulaires a stabilite amelioree
|
KR20060109481A
(ko)
*
|
2003-12-04 |
2006-10-20 |
화이자 프로덕츠 인코포레이티드 |
바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
WO2005053639A2
(fr)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
|
US8883204B2
(en)
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
US20070269505A1
(en)
*
|
2003-12-09 |
2007-11-22 |
Flath Robert P |
Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
|
PT1691811E
(pt)
|
2003-12-11 |
2014-10-30 |
Sunovion Pharmaceuticals Inc |
Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
|
TWI365880B
(en)
*
|
2004-03-30 |
2012-06-11 |
Euro Celtique Sa |
Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
|
WO2005097075A2
(fr)
|
2004-03-30 |
2005-10-20 |
Euro-Celtique S.A. |
Forme posologique resistant aux violations, comprenant un absorbant et un agent adverse
|
EP1748762B1
(fr)
|
2004-05-28 |
2013-12-18 |
AbbVie Deutschland GmbH & Co KG |
Forme de dosage obtensible à partir d'un mélange de poudres contenant un pigment inorganique
|
EP1604667A1
(fr)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioides pour le traitement des impatiences des membres inférieurs
|
EP1604666A1
(fr)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioides pour le traitement de la bronchopneumopathie chronique obstructive
|
DK1765292T3
(en)
|
2004-06-12 |
2018-01-02 |
Collegium Pharmaceutical Inc |
ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
MX2007009162A
(es)
*
|
2005-01-28 |
2007-10-23 |
Euro Celtique Sa |
Formas de dosis rsistente al alcohol.
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1695700A1
(fr)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Forme posologique contenant de l'oxycodone et de la naloxone
|
EP1702558A1
(fr)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Procédé et dispositif pour évaluer la fonction de l'activité intestinale
|
DE602006016127D1
(de)
*
|
2005-07-05 |
2010-09-23 |
Abbott Gmbh & Co Kg |
Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
|
US8486456B2
(en)
|
2005-08-08 |
2013-07-16 |
Abbott Gmbh & Co., Kg |
Itraconazole compositions with improved bioavailability
|
JP2009504590A
(ja)
|
2005-08-08 |
2009-02-05 |
アボット ゲーエムベーハー ウント コンパニー カーゲー |
改善された生物学的利用能をもつ剤型
|
EP1991207A2
(fr)
*
|
2006-01-21 |
2008-11-19 |
Abbott GmbH & Co. KG |
Forme dosifiée et méthode d'administration de drogues toxicomanogènes
|
EP1813276A1
(fr)
*
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Formes de dosage inviolables
|
EP1832281A1
(fr)
*
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Procédé pour la production d'une dispersion solide d'un ingredient actif
|
KR20140079441A
(ko)
|
2006-06-19 |
2014-06-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
CA2669938C
(fr)
*
|
2006-11-15 |
2016-01-05 |
Abbott Laboratories |
Formulations de dosage pharmaceutique solides
|
GB0624880D0
(en)
*
|
2006-12-14 |
2007-01-24 |
Johnson Matthey Plc |
Improved method for making analgesics
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
JP2011506319A
(ja)
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
WO2009092601A1
(fr)
|
2008-01-25 |
2009-07-30 |
Grünenthal GmbH |
Forme posologique pharmaceutique
|
MX2010012039A
(es)
|
2008-05-09 |
2010-11-30 |
Gruenenthal Gmbh |
Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
EP3045043B1
(fr)
|
2009-02-26 |
2020-04-29 |
Relmada Therapeutics, Inc. |
Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
|
JP5886632B2
(ja)
|
2009-03-10 |
2016-03-16 |
ユーロ−セルティーク エス.エイ. |
オキシコドンおよびナロキソンを含む即時放出医薬組成物
|
BR112012001547A2
(pt)
|
2009-07-22 |
2016-03-08 |
Gruenenthal Gmbh |
forma de dosagem farmacêutica extrusada por fusão a quente
|
RU2567723C2
(ru)
|
2009-07-22 |
2015-11-10 |
Грюненталь Гмбх |
Стабильная при окислении, прочная на излом лекарственная форма
|
EP2477593A1
(fr)
*
|
2009-09-18 |
2012-07-25 |
Basf Se |
Procédé pour produire des préparations de substances peu solubles dans l'eau
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
ES2606227T3
(es)
|
2010-02-03 |
2017-03-23 |
Grünenthal GmbH |
Preparación de una composición farmacéutica en polvo mediante una extrusora
|
RU2604676C2
(ru)
|
2010-09-02 |
2016-12-10 |
Грюненталь Гмбх |
Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
|
PE20131126A1
(es)
|
2010-09-02 |
2013-10-21 |
Gruenenthal Chemie |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico
|
PL2826467T3
(pl)
|
2010-12-22 |
2018-01-31 |
Purdue Pharma Lp |
Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
DK2736497T3
(da)
|
2011-07-29 |
2017-11-13 |
Gruenenthal Gmbh |
Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
|
CA2839123A1
(fr)
|
2011-07-29 |
2013-02-07 |
Grunenthal Gmbh |
Comprime anti-manipulation permettant une liberation immediate de medicament
|
US20130225697A1
(en)
|
2012-02-28 |
2013-08-29 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
WO2013156453A1
(fr)
|
2012-04-18 |
2013-10-24 |
Grünenthal GmbH |
Forme pharmaceutique inviolable et résistante à la libération massive
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
AR091779A1
(es)
|
2012-07-16 |
2015-02-25 |
Rhodes Technologies |
Procedimiento para la sintesis mejorada de opioides
|
NZ628699A
(en)
|
2012-07-16 |
2016-05-27 |
Rhodes Technologies |
Process for improved opioid synthesis
|
AP2015008579A0
(en)
|
2013-02-05 |
2015-07-31 |
Purdue Pharma Lp |
Tamper resistant pharmaceutical formulations
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
AU2014233453A1
(en)
|
2013-03-15 |
2015-10-01 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
AR096438A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
|
CA2907950A1
(fr)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Forme pharmaceutique inviolable contenant une ou plusieurs particules
|
AU2014289187B2
(en)
|
2013-07-12 |
2019-07-11 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
KR20160034352A
(ko)
|
2013-07-23 |
2016-03-29 |
유로-셀티큐 에스.에이. |
장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
|
US9120800B2
(en)
|
2013-08-02 |
2015-09-01 |
Johnson Matthey Public Limited Company |
Process for the preparation of oxymorphone alkaloid and oxymorphone salts
|
MX371372B
(es)
|
2013-11-26 |
2020-01-28 |
Gruenenthal Gmbh |
Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
|
AU2015207733A1
(en)
|
2014-01-15 |
2016-07-14 |
Rhodes Technologies |
Process for improved oxycodone synthesis
|
TWI539952B
(zh)
|
2014-01-15 |
2016-07-01 |
羅德科技公司 |
改良氧化嗎啡酮合成之方法
|
US9062063B1
(en)
|
2014-03-21 |
2015-06-23 |
Johnson Matthey Public Limited Company |
Forms of oxymorphone hydrochloride
|
EP3142646A1
(fr)
|
2014-05-12 |
2017-03-22 |
Grünenthal GmbH |
Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
|
JP2017516789A
(ja)
|
2014-05-26 |
2017-06-22 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
エタノール過量放出に対して防護されている多粒子
|
US9918979B2
(en)
|
2015-01-29 |
2018-03-20 |
Johnson Matthey Public Limited Company |
Process of preparing low ABUK oxymorphone hydrochloride
|
KR20170139158A
(ko)
|
2015-04-24 |
2017-12-18 |
그뤼넨탈 게엠베하 |
즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
|
CA2998259A1
(fr)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|